Mar 01st 2013 - Edison Investment Research today published a report on quickview entitled "Jaking Up The Sales". In summary, the report says:
A second strong quarter in a row for Jakafi (ruxolitinib) has enabled Incyte to set ambitious 2013 sales guidance for the product at $210-225m, representing 54-65% y-o-y growth. The strong Q4 performance was driven by volume (+17%), inventory (+4%) and price increase (+4%) vs Q3. Incyte expects continuing quarter-on-quarter unit growth (high single to low double digit) with a lower discontinuation rate in 2013. Jakavi (the ex-US brand name) is now approved in over 30 countries and Incyte receives royalties from Novartis in the high teens to mid-20% range.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
